A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.

ABSTRACT:

Rationale

Roflumilast is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD). It has antiinflammatory effects; however, it is not known whether it can affect a biologic pathway implicated in COPD pathogenesis and progression. The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD. AcPGP is produced by extracellular matrix collagen breakdown with prolyl endopeptidase and leukotriene A4 hydrolase serving as the enzymes responsible for its production and degradation, respectively.

Objectives

We hypothesized that roflumilast would decrease AcPGP, halting the feed-forward cycle of inflammation.

Methods

We conducted a single-center, place

SUBMITTER: Wells JM 

PROVIDER: S-EPMC4642210 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature